Vlad Ratziu

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong et al. · Journal of Hepatology · 2024 · 1.6K citations · Full text

Medicine, Internal Medicine, Hepatology +9

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Philip N. Newsome, Iris Kliers, Laura Østergaard et al. · New England Journal of Medicine · 2025 · 690 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effect of Treatment With Peginterferon or Interferon Alfa–2B and Ribavirin on Steatosis in Patients Infected With Hepatitis C

Thierry Poynard, Vlad Ratziu, John G. McHutchison et al. · Hepatology · 2003 · 601 citations

Pharmacy, Internal Medicine, Pharmacotherapy +17

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 472 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11